Mutational analysis confirms the presence of distal inhibitor-selectivity determining residues in B. stearothermophilus dihydrofolate reductase.
Mutational analysis confirms the presence of distal inhibitor-selectivity determining residues in B. stearothermophilus dihydrofolate reductase.
复制标题
突变分析证实嗜热脂肪芽孢杆菌二氢叶酸还原酶中存在远端抑制剂选择性决定残基。
DOI:
10.1016/j.abb.2020.108545
复制
发表时间:
2020
影响因子:
3.9
通讯作者:
Goodey,NinaM
中科院分区:
文献类型:
--
作者:
Eck,Tyler;Patel,Seema;Candela,Thomas;LeonH,Katherine;Little,Michael;Reis,NataliaE;Liyanagunawardana,Uththara;Gubler,Ueli;Janson,CherylA;Catalano,Jaclyn;Goodey,NinaM
Many antibacterial and antiparasitic drugs work by competitively inhibiting dihydrofolate reductase (DHFR), a vital enzyme in folate metabolism. The interactions between inhibitors and DHFR active site residues are known in many homologs but the contributions from distal residues are less understood. Identifying distal residues that aid in inhibitor binding can improve targeted drug development programs by accounting for distant influences that may be less conserved and subject to frequent resistance causing mutations. Previously, a novel, homology-based, computational approach that mines ligand inhibition data was used to predict residues involved in inhibitor selectivity in the DHFR family. Expectedly, some inhibitor selectivity determining residue positions were predicted to lie in the active site and coincide with experimentally known inhibitor selectivity determining positions. However, other residues that group spatially in clusters distal to the active site have not been previously investigated. In this study, the effect of introducing amino acid substitutions at one of these predicted clusters (His38-Ala39-Ile40) on the inhibitor selectivity profile inBacillus stearothermophilusdihydrofolate reductase (BsDHFR) was investigated. Mutations were introduced into these cluster positions to change sidechain chemistry and size. We determinedkcatand KMvalues and measured KDvalues at equilibrium for two competitive DHFR inhibitors, trimethoprim (TMP) and pyrimethamine (PYR). Mutations in the His38-Ala39-Ile40 cluster significantly impacted inhibitor binding and TMP/PYR selectivity - seven out of nine mutations resulted in tighter binding to PYR when compared to TMP. These data suggest that the His38-Ala39-Ile40 cluster is a distal inhibitor selectivity determining region that favors PYR binding inBsDHFR and, possibly, throughout the DHFR family.